Intensity Therapeutics Raises $6.6 Million in July 2025 Through At-The-Market Stock Sales

Intensity Therapeutics, Inc. (Nasdaq: INTS), a biotechnology firm at the forefront of developing intratumoral cancer therapies, reported a significant financial boost in July 2025. The company successfully raised $6.6 million gross ($6.3 million net) by selling 19,868,658 shares of its common stock through an At-the-Market (ATM) offering. This strategic move, executed at an average price of $0.3323 per share, has left the company with 46,035,081 shares of common stock issued and outstanding as of July 31, 2025.

Lewis H. Bender, President and CEO of Intensity, highlighted the advantages of this financial strategy, noting the favorable stock prices and liquidity conditions that facilitated the capital raise. The proceeds are earmarked for advancing the company's clinical trials into the latter half of 2026, underscoring the importance of this funding in sustaining the momentum of their research and development efforts.

Intensity's lead investigational product, INT230-6, represents a novel approach to cancer treatment. Designed for direct intratumoral injection, INT230-6 leverages the company's proprietary DfuseRx℠ technology to deliver potent anti-cancer agents directly to the tumor, promoting local disease control and stimulating an immune response against the cancer. This method offers a promising alternative to traditional systemic chemotherapy, with the potential to transform the treatment landscape for various cancers.

The company's ongoing clinical trials, including Phase 3 studies in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer, are critical steps toward validating the efficacy and safety of INT230-6. For more information on Intensity Therapeutics and its groundbreaking work in cancer therapy, visit https://www.intensitytherapeutics.com.